Shockwave Medical Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 3/6

Shockwave Medical verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 67.5%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 12%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 57.6%. Die Eigenkapitalrendite von Shockwave Medical beträgt 21.7% und die Nettomargen betragen 20.7%.

Wichtige Informationen

67.5%

Wachstumsrate der Gewinne

74.9%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie	8.9%
Wachstumsrate der Einnahmen	57.6%
Eigenkapitalrendite	21.7%
Netto-Marge	20.7%
Nächste Ertragsaktualisierung	05 Aug 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Apr 06

Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Mar 24

Shockwave Medical: Opening Arteries, Delivering Returns

Feb 28

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 18

There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Feb 06

Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

Jan 24

Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

Jan 09

Aufschlüsselung der Einnahmen und Ausgaben

Wie Shockwave Medical Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:SWAV Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	788	163	354	163
31 Dec 23	730	147	323	146
30 Sep 23	671	244	293	127
30 Jun 23	617	244	277	108
31 Mar 23	557	241	244	92
31 Dec 22	490	216	219	82
30 Sep 22	430	88	201	73
30 Jun 22	364	55	183	66
31 Mar 22	299	29	163	57
31 Dec 21	237	-9	146	51
30 Sep 21	176	-38	126	45
30 Jun 21	130	-53	108	39
31 Mar 21	84	-71	90	35
31 Dec 20	68	-66	76	37
30 Sep 20	59	-65	67	38
30 Jun 20	51	-65	59	38
31 Mar 20	51	-57	53	37
31 Dec 19	43	-51	45	33
30 Sep 19	34	-48	37	29
30 Jun 19	26	-45	32	26
31 Mar 19	18	-44	28	25
31 Dec 18	12	-41	24	23
31 Dec 17	2	-31	12	18

Qualität der Erträge: SWAV hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: SWAVDie aktuellen Gewinnspannen (20.7%) sind niedriger als im letzten Jahr (43.2%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: SWAV ist in den letzten 5 Jahren profitabel geworden und hat seinen Gewinn um 67.5% pro Jahr gesteigert.

Beschleunigtes Wachstum: SWAVDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: SWAV hatte im vergangenen Jahr ein negatives Gewinnwachstum (-32%), was einen Vergleich mit dem Branchendurchschnitt Medical Equipment (10.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: SWAVDie Eigenkapitalrendite des Unternehmens (21.7%) wird als hoch angesehen.

Shockwave Medical Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Price target increased by 7.7% to US$302

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Price target increased by 9.7% to US$286

Insufficient new directors

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Chief Commercial Officer notifies of intention to sell stock

Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Independent Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Shockwave Medical: Opening Arteries, Delivering Returns

New minor risk - Shareholder dilution

Independent Director recently sold US$15m worth of stock

Now 21% undervalued

Consensus EPS estimates increase by 12%

President exercised options and sold US$2.3m worth of stock

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2023 earnings: EPS exceeds analyst expectations

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Chief Commercial Officer notifies of intention to sell stock

Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

President notifies of intention to sell stock

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

President notifies of intention to sell stock

Is Shockwave Medical (NASDAQ:SWAV) A Risky Investment?

Chief Commercial Officer notifies of intention to sell stock

President exercised options and sold US$922k worth of stock

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Now 21% undervalued after recent price drop

President notifies of intention to sell stock

What Is Shockwave Medical, Inc.'s (NASDAQ:SWAV) Share Price Doing?

Investor sentiment deteriorates as stock falls 25%

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Now 22% undervalued after recent price drop

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to US$241

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Is Shockwave Medical, Inc. (NASDAQ:SWAV) Trading At A 50% Discount?

President notifies of intention to sell stock

Shockwave Medical (NASDAQ:SWAV) Is Very Good At Capital Allocation

Shockwave Medical (NASDAQ:SWAV) Has A Rock Solid Balance Sheet

President notifies of intention to sell stock

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 10%, revenue upgraded

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

When Should You Buy Shockwave Medical, Inc. (NASDAQ:SWAV)?

We Think Shockwave Medical (NASDAQ:SWAV) Might Have The DNA Of A Multi-Bagger

Chief Commercial Officer notifies of intention to sell stock

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index